GB Patent

GB2487712B — Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy

Assigned to GW Pharma Ltd · Expires 2015-10-28 · 11y expired

What this patent protects

Patent listed against fenfluramine-hydrochloride.

Drugs covered by this patent

fenfluramine-hydrochloride (FENFLURAMINE HYDROCHLORIDE)

Patent Metadata

Patent number: GB2487712B
Jurisdiction: GB
Classification: —
Expires: 2015-10-28
Drug substance claim: No
Drug product claim: No
Assignee: GW Pharma Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.